Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Urine Studies II: Urine Culture and Sensitivity Test01:26

Urine Studies II: Urine Culture and Sensitivity Test

98
A urine culture and sensitivity test is a diagnostic procedure used to identify urinary tract bacterial infections and determine the most effective antibiotics for treatment. This test is generally preferred when a patient shows manifestations of a urinary tract infection, such as frequent or painful urination, cloudy or foul-smelling urine, or lower abdominal pain.Purpose of the TestThe primary goals of a urine culture and sensitivity test are to:Determine the specific bacteria causing the...
98
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

135
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
135

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk factors and clinical impact of multidrug resistance in healthcare-associated bacteraemic urinary tract infections: a post-hoc analysis of a multicentre prospective cohort in Spain.

The Journal of hospital infection·2024
Same author

Progression of subclinical cardiovascular disease in patients with HIV.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2024
Same author

Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2023
Same author

Are GES carbapenemases underdiagnosed? An allelic discrimination assay for their accurate detection and differentiation.

Journal of microbiological methods·2023
Same author

The poor accuracy of D-dimer for the diagnosis of prosthetic joint infection but its potential usefulness in early postoperative infections following revision arthroplasty for aseptic loosening.

BMC infectious diseases·2022
Same author

Clinical management of cUTI, cIAI, and HABP/VABP attributable to carbapenem-resistant Gram-negative infections in Spain.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2021

Related Experiment Video

Updated: Aug 26, 2025

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.7K

Clinical experience of cefiderocol.

M C Fariñas1

  • 1María Carmen Fariñas, Servicio de Enfermedades Infecciosas, Hospital Universitario Marqués de Valdecilla. Universidad de Cantabria. Santander. Cantabria, Spain. mcarmen.farinas@scsalud.es.

Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia
|October 4, 2022
PubMed
Summary

Antimicrobial resistance causes hundreds of thousands of deaths annually, projected to reach ten million by 2050. Cefiderocol offers a new treatment option against resistant gram-negative bacterial infections, saving patient lives.

More Related Videos

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.1K
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.2K

Related Experiment Videos

Last Updated: Aug 26, 2025

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.7K
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.1K
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.2K

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Microbiology

Background:

  • Antimicrobial resistance (AMR) is a growing global health crisis, causing significant mortality.
  • Projections estimate AMR deaths will reach ten million annually by 2050, highlighting an urgent need for effective treatments.
  • Hospital-acquired infections, including complicated urinary tract infections and pneumonia, are frequently caused by resistant pathogens.

Purpose of the Study:

  • To introduce cefiderocol as a novel cephalosporin with a unique mechanism of action.
  • To highlight cefiderocol's potential as a crucial therapeutic agent against multidrug-resistant (MDR) aerobic gram-negative bacteria.
  • To review the clinical applications of cefiderocol in treating severe infections.

Main Methods:

  • Review of cefiderocol's mechanism of action as a siderophore cephalosporin.
  • Analysis of clinical data and usage in treating various resistant infections.
  • Evaluation of cefiderocol's efficacy in complicated urinary tract infections (cUTI), hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and sepsis.

Main Results:

  • Cefiderocol demonstrates effectiveness against a range of resistant aerobic gram-negative bacteria.
  • Clinical use has shown promise in treating patients with cUTI, HAP, VAP, sepsis, and bacteremia.
  • The drug's novel mechanism provides a vital option for infections unresponsive to other antimicrobials.

Conclusions:

  • Cefiderocol represents a significant advancement in combating infections caused by antibiotic-resistant pathogens.
  • Its unique properties make it an essential tool for clinicians managing severe gram-negative bacterial infections.
  • Effective antimicrobial therapy, such as with cefiderocol, is critical for improving patient outcomes and saving lives in the face of the AMR 'stealth pandemic'.